

Serial No. 09/_____

REMARKS/ARGUMENTS

Consideration of the captioned application in view of the foregoing amendments and following remarks is requested.

The specification has been amended to refer to the priority applications.

Claims 7 and 8 have been canceled. European style use claim 9 has been canceled and replaced with new claims 13-17. Support for claims 13-17 can be found, for example, at original claim 9.

Claims 18-20 have been added to present claims of varying scope. Support for new claims 18-20 can be found, for example, at original claims 3 and 4.

Accordingly, the claims pending are claims 1-6 and 10-20.

Enclosed herewith is an Information Disclosure Statement with a copy of the International Search Report and documents cited therein.


Early favorable action on the merits is respectfully requested.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page(s) is/are captioned "Version with markings to show changes made".

Serial No. 09/_____

Applicant respectfully requests that a timely Notice of Allowance be issued in this case.

Respectfully submitted,



Steven P. Berman
Reg. No. 24,772

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-2359
Dated: October 19, 2001

Serial No. 09/_____

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Specification:

Page 1, between the Title and line 4, please insert the following:

--- Cross Reference to Related Applications

This application is a continuation application of the national stage of application no. PCT/EP98/04022, filed June 22, 1998 which application claims priority from EP 97201931.9, filed June 24, 1997 and US provisional application no. 60/053003, filed July 10, 1997. ---

In the Claims:

3. (Amended) A compound according to [any of claims] claim 1 [or 2] wherein X is N; R¹ is hydrogen, C₁₋₄alkyl or di(C₁₋₄alkyl)amino; R² is hydrogen; R³, R⁴ and R⁵ are each independently selected from hydrogen, halo, C₁₋₄alkyl, C₁₋₄alkyloxy or trifluoromethyl; and the bivalent radical —A— is Ar², Ar²CH₂- or Het² wherein Ar² is phenyl and Het² is thiadiazolyl, pyridinyl, pyrimidinyl or pyrazinyl. [.]

4. (Amended) A compound according to [any of claims] claim 1 [to 3] wherein X is N, R¹ is methyl, R² is hydrogen, R³ and R⁴ are hydrogen and R⁵ is trifluoromethyl

Serial No. 09/_____

6. (Amended) A composition comprising a pharmaceutically acceptable carrier, and as active ingredient a therapeutically effective amount of a compound as claimed in [any one of claims] claim 1 [to 5].

Please cancel claims 7 and 8.

Please cancel claim 9 and replace with new claims 13-17.

13. (New) A method of treating angiogenesis dependent disorders comprising administering to a host in need thereof an effective amount of a compound of claim 1.

14. (New) A method of treating angiogenesis dependent disorders comprising administering to a host in need thereof an effective amount of a compound of claim 2.

15. (New) A method of treating angiogenesis dependent disorders comprising administering to a host in need thereof an effective amount of a compound of claim 3.

16. (New) A method of treating angiogenesis dependent disorders comprising administering to a host in need thereof an effective amount of a compound of claim 4.

17. (New) A method of treating angiogenesis dependent disorders comprising administering to a host in need thereof an effective amount of a compound of claim 5.

Please add the following new claims 18-20.

18. (New) A compound according to claim 2 wherein X is N; R¹ is hydrogen, C₁₋₄alkyl or di(C₁₋₄alkyl)amino; R² is hydrogen;

Serial No. 09/_____

R^3 , R^4 and R^5 are each independently selected from hydrogen, halo, C_{1-4} alkyl, C_{1-4} alkyloxy or trifluoromethyl; and the bivalent radical $\text{---} \bigcirc \text{---}$ is Ar^2 , $Ar^2\text{CH}_2\text{-}$ or Het^2 wherein Ar^2 is phenyl and Het^2 is thiadiazolyl, pyridinyl, pyrimidinyl or pyrazinyl.

19. (New) A compound according to claim 2 wherein X is N, R^1 is methyl, R^2 is hydrogen, R^3 and R^4 are hydrogen and R^5 is trifluoromethyl.

20. (New) A compound according to claim 3 wherein X is N, R^1 is methyl, R^2 is hydrogen, R^3 and R^4 are hydrogen and R^5 is trifluoromethyl.